Incretin Atlas › Trials › ATTAIN-2 (obesity + T2D)
ATTAIN-2 (obesity + T2D)
Orforglipron · t2d
Design
- Molecule(s)
- Orforglipron
- Population
- t2d
- Official title
- A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- Sponsor
- Eli Lilly and Company
- Phase
- 3
- Registry status
- completed · 2023-06 → 2025-08
- Participants
- 1613
- Duration
- 72 weeks
- Registry
- NCT05872620
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| orforglipron 6 mg | t2d | 72 | 1613 | −5.5 % vs −2.2 % Δ −3.3 pp | −5.1 % vs −2.5 % Δ −2.6 pp | −1.2 vs −0.5 | 6.1 vs 4.6 | 19.1 vs 20.0 | 20.1 vs 8.4 | 12.8 vs 3.8 | 7.3 vs 8.8 | — | verified |
| orforglipron 12 mg | t2d | 72 | 1613 | −7.8 % vs −2.2 % Δ −5.6 pp | −7.0 % vs −2.5 % Δ −4.5 pp | −1.5 vs −0.5 | 10.6 vs 4.6 | 22.3 vs 20.0 | 31.1 vs 8.4 | 20.2 vs 3.8 | 10.3 vs 8.8 | — | verified |
| orforglipron 36 mg | t2d | 72 | 1613 | −10.5 % vs −2.2 % Δ −8.3 pp | −9.6 % vs −2.5 % Δ −7.1 pp | −1.7 vs −0.5 | 10.6 vs 4.6 | 20.5 vs 20.0 | 36.4 vs 8.4 | 23.1 vs 3.8 | 10.9 vs 8.8 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- orforglipron 6 mg: 329 of 1613 participants randomised to this arm (placebo 630). HbA1c: treatment-regimen estimand (Table 2). Any discontinuation = participants who discontinued the intervention / randomised (Figure 1). Systolic blood pressure is reported by dose only in a figure panel and is not shown.
- orforglipron 12 mg: 332 of 1613 participants randomised to this arm (placebo 630). HbA1c: treatment-regimen estimand (Table 2). Any discontinuation = participants who discontinued the intervention / randomised (Figure 1). Systolic blood pressure is reported by dose only in a figure panel and is not shown.
- orforglipron 36 mg: 322 of 1613 participants randomised to this arm (placebo 630). HbA1c: treatment-regimen estimand (Table 2). Any discontinuation = participants who discontinued the intervention / randomised (Figure 1). Systolic blood pressure is reported by dose only in a figure panel and is not shown.
Verbatim quotes from the source (24)
- orforglipron 6 mg · weight_tp · Summary / Table 2 (treatment regimen estimand)
the mean percent change in bodyweight from baseline to week 72 was –5·1% (95% CI –6·0 to –4·2) with 6 mg (estimated treatment difference [ETD] –2·7 [95% CI –3·7 to –1·6]; p<0·0001)
- orforglipron 6 mg · weight_eff · Results, efficacy estimand (figure 2B)
For the efficacy estimand, the mean percent change from baseline in bodyweight to week 72 was -5.5% (95% CI -6.2 to -4.8) or -5.5 kg with orforglipron 6 mg, -7.8% (-8.6 to -7.0) or -7.9 kg with orforglipron 12 mg, -10.5% (-11.5 to -9.6) or -10.4 kg with orforglipron 36 mg, and -2.2% (-2.6 to -1.8) or -2.3 kg with placebo
- orforglipron 6 mg · ae_dc · Table 4
Adverse events leading to discontinuation of study drug 20 (6·1%) 35 (10·6%) 34 (10·6%) 29 (4·6%)
- orforglipron 6 mg · disc_any · Figure 1 trial profile; computed: 63/329 vs 126/630 with placebo
63 discontinued intervention
- orforglipron 6 mg · nausea · Table 4
Nausea 66 (20·1%) 103 (31·1%) 117 (36·4%) 53 (8·4%)
- orforglipron 6 mg · vomiting · Table 4
Vomiting 42 (12·8%) 67 (20·2%) 74 (23·1%) 24 (3·8%)
- orforglipron 6 mg · sae · Table 4
Serious adverse events 24 (7·3%) 34 (10·3%) 35 (10·9%) 55 (8·8%)
- orforglipron 6 mg · hba1c · Table 2
Change in HbA1c, % (95% CI) –1·22 (–1·36 to –1·08) –1·50 (–1·62 to –1·38) –1·66 (–1·77 to –1·55) –0·47 (–0·58 to –0·36) Treatment comparison (95% CI); p value ETD –0·76 (–0·93 to –0·58); p<0·0001 ETD –1·03 (–1·19 to –0·87); p<0·0001 ETD –1·20 (–1·35 to –1·04); p<0·0001
- orforglipron 12 mg · weight_tp · Summary / Table 2 (treatment regimen estimand)
–7·0% (–7·8 to –6·2) with 12 mg (ETD –4·5 [–5·5 to –3·6]; p<0·0001)
- orforglipron 12 mg · weight_eff · Results, efficacy estimand (figure 2B)
For the efficacy estimand, the mean percent change from baseline in bodyweight to week 72 was -5.5% (95% CI -6.2 to -4.8) or -5.5 kg with orforglipron 6 mg, -7.8% (-8.6 to -7.0) or -7.9 kg with orforglipron 12 mg, -10.5% (-11.5 to -9.6) or -10.4 kg with orforglipron 36 mg, and -2.2% (-2.6 to -1.8) or -2.3 kg with placebo
- orforglipron 12 mg · ae_dc · Table 4
Adverse events leading to discontinuation of study drug 20 (6·1%) 35 (10·6%) 34 (10·6%) 29 (4·6%)
- orforglipron 12 mg · disc_any · Figure 1 trial profile; computed: 74/332 vs 126/630 with placebo
74 discontinued intervention
- orforglipron 12 mg · nausea · Table 4
Nausea 66 (20·1%) 103 (31·1%) 117 (36·4%) 53 (8·4%)
- orforglipron 12 mg · vomiting · Table 4
Vomiting 42 (12·8%) 67 (20·2%) 74 (23·1%) 24 (3·8%)
- orforglipron 12 mg · sae · Table 4
Serious adverse events 24 (7·3%) 34 (10·3%) 35 (10·9%) 55 (8·8%)
- orforglipron 12 mg · hba1c · Table 2
Change in HbA1c, % (95% CI) –1·22 (–1·36 to –1·08) –1·50 (–1·62 to –1·38) –1·66 (–1·77 to –1·55) –0·47 (–0·58 to –0·36) Treatment comparison (95% CI); p value ETD –0·76 (–0·93 to –0·58); p<0·0001 ETD –1·03 (–1·19 to –0·87); p<0·0001 ETD –1·20 (–1·35 to –1·04); p<0·0001
- orforglipron 36 mg · weight_tp · Summary / Table 2 (treatment regimen estimand)
–9·6% (–10·5 to –8·7) with 36 mg orforglipron (ETD –7·1 [–8·2 to –6·1]; p<0·0001)
- orforglipron 36 mg · weight_eff · Results, efficacy estimand (figure 2B)
For the efficacy estimand, the mean percent change from baseline in bodyweight to week 72 was -5.5% (95% CI -6.2 to -4.8) or -5.5 kg with orforglipron 6 mg, -7.8% (-8.6 to -7.0) or -7.9 kg with orforglipron 12 mg, -10.5% (-11.5 to -9.6) or -10.4 kg with orforglipron 36 mg, and -2.2% (-2.6 to -1.8) or -2.3 kg with placebo
- orforglipron 36 mg · ae_dc · Table 4
Adverse events leading to discontinuation of study drug 20 (6·1%) 35 (10·6%) 34 (10·6%) 29 (4·6%)
- orforglipron 36 mg · disc_any · Figure 1 trial profile; computed: 66/322 vs 126/630 with placebo
66 discontinued intervention
- orforglipron 36 mg · nausea · Table 4
Nausea 66 (20·1%) 103 (31·1%) 117 (36·4%) 53 (8·4%)
- orforglipron 36 mg · vomiting · Table 4
Vomiting 42 (12·8%) 67 (20·2%) 74 (23·1%) 24 (3·8%)
- orforglipron 36 mg · sae · Table 4
Serious adverse events 24 (7·3%) 34 (10·3%) 35 (10·9%) 55 (8·8%)
- orforglipron 36 mg · hba1c · Table 2
Change in HbA1c, % (95% CI) –1·22 (–1·36 to –1·08) –1·50 (–1·62 to –1·38) –1·66 (–1·77 to –1·55) –0·47 (–0·58 to –0·36) Treatment comparison (95% CI); p value ETD –0·76 (–0·93 to –0·58); p<0·0001 ETD –1·03 (–1·19 to –0·87); p<0·0001 ETD –1·20 (–1·35 to –1·04); p<0·0001
Primary sources
- Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927-2944. PMID: 41275875.
- Eli Lilly and Company. A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) (ATTAIN-2). ClinicalTrials.gov identifier NCT05872620. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05872620
How to cite this page
Medical Adviser's Group. Incretin Atlas: ATTAIN-2 (obesity + T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.